Latin America Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Latin America Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Latin America Alpha-Glucosidase Inhibitors Market is expected to register a CAGR greater than 3% over the forecast period.

The COVID-19 pandemic has been testing the capacity to respond and adapt to populations, governments, and health systems worldwide. In the Latin America region, Brazil presented the first suspected and the first confirmed cases on January 27th and February 26th, respectively. Most Latin American countries failed to implement timely measures to protect individuals with diabetes, which may severely impact individuals, health systems, and economies.

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.

This is driving the demand for Alpha-Glucosidase Inhibitors in Latin America, thereby driving the market in focus during the forecast period.​

Key Market TrendsRising Diabetes Prevalence in Latin America Region

In Latin America, the incidence of type 1 diabetes ranges from 0.4 to 8.3 cases per 100,000 children under the age of 15, and the prevalence of type 2 diabetes ranges from 1.2% to 8%, with higher prevalence rates in urban areas. Diabetes is expected to increase by 38% in Latin America over the next decade, compared to a 14% increase in the total population. By 2025, the total number of diabetes cases is expected to more than double and surpass the number of cases.

Factors contributing to this increase include population aging and increased life expectancy, increased urbanization, and lifestyle changes among Native American populations. Diabetes treatment is currently available to only a minority of people in many places. Furthermore, type 2 diabetes is frequently diagnosed late in the disease's progression, resulting in 10-40% of patients having chronic complications at the time of diagnosis. Hospital costs account for the majority of direct treatment costs, and diabetes mortality has increased significantly in some areas over the last two decades.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Latin America Region.

Brazil is Expected to Dominate the Latin America Alpha-Glucosidase Inhibitors Market.

Among the Latin American countries, Brazil dominates around 79% of the total Latin America Alpha-Glucosidase Inhibitors Market. This is mainly due to the high diabetes prevalence in the country. In Brazil, the Brazilian health system is managed by each state and local health secretariat and is governed by the MOH. Furthermore, in many towns where the public sector is unable to meet people's requirements, partnerships with private organizations to increase access to PHC have been put in place. The Brazilian health system in Brazil provides coverage to medicines through several programs that include a 20% expanded access to essential medicines. Brazil offers an extensive free immunization program. Brazil faced numerous lawsuits over the last 20 years, demanding the coverage of high-cost drugs to treat diabetes and certain rare or low-prevalence diseases.

According to Universal Health Coverage 2022, The four nations including Argentina, Brazil, Colombia, and Mexico achieved an overall index of essential coverage of 76-77 percent, with households spending less than 25 percent of their income on health care. Expanding access to primary healthcare systems and coverage for noncommunicable illnesses enhanced service coverage, while a rise in the number of qualified healthcare personnel enabled community outreach.

AGIs are effective in improving the metabolic profile and potentially lowering the risk of long-term hyperglycemia complications in patients with type 2 diabetes mellitus. They can be used alone or in combination with other antihyperglycemic medications and insulin. They have no links to any serious negative consequences. This makes them especially useful for patients with renal, cardiorespiratory, or liver issues, who are at a higher risk of developing lactic acidosis and thus are not good candidates for metformin therapy. They also do not cause hypoglycemia, making them a viable alternative to sulfonylureas, which are frequently associated with hypoglycemia. Patients should be counseled on how to maintain an appropriate diet, as a high carbohydrate diet can exacerbate gastrointestinal side effects. If used in conjunction with other anti-diabetic medications, the patient should keep glucose on hand in order to quickly reverse hypoglycemia. Type 2 diabetes mellitus management necessitates an interdisciplinary approach; the primary care provider, pharmacist, and nurse practitioner should educate patients about side effects and instruct them on how to maintain an appropriately healthy diet.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in Latin America Region.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.